昊海生物科技(06826.HK)上半年純利降69.25%至7103萬元 加大研發着重擴充眼科和醫美創新產品線
格隆匯8月26日丨昊海生物科技(06826.HK)公佈,截至2022年6月30日止六個月,集團營業收入約人民幣9.56億元,同比增長約13.05%;公司普通股權益持有人應占利潤約為人民幣7103萬元,同比減少約69.25%;每股基本盈利為人民幣0.41元。
報吿期內,集團持續加大研發投入,着重擴充眼科和醫美創新產品線,研發費用約為人民幣7671萬元,較2021年同期增加4.38%。研發費用佔營業收入比重持續維持高位,達到8.02%。
2022年上半年,上海及周邊城市自二月份起經歷了嚴峻的新冠肺炎疫情的挑戰,公司及其位於上海地區的三家主要生產型子公司的供應鏈等各環節的正常運營均受到影響。直到2022年六月初疫情趨緩,上海陸續解除全域靜態管理,公司經營得以逐步恢復。雖然公司在做好防疫工作的基礎上積極組織生產、發貨,儘量降低疫情產生的影響,併力爭在2022年六月予以彌補,但整體上,公司及上海地區子公司的營業收入仍較2021年同期有所下降。與此同時,公司位於上海以外地區的子公司努力克服各地散發疫情,積極開拓市場,報吿期內,集團國產人工晶狀體產品線營業收入較2021年同期實現了顯著增長。此外,報吿期內,集團較2021年同期新增角膜塑形鏡產品、射頻及激光設備產品,相關產品銷售收入抵消了前述上海地區疫情對收入下降的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.